Dept. of Urology, Jichi Medical University.

We have treated 8 patients with metastatic renal cell carcinoma for whom prior immunotherapy proved uneffective. The patients consisted of 6 males and 2 females, with a median age of 68 years. One patient had a primary site in place and 5 patients had multiple organs involvement. The chemotherapy consisted of gemcitabine 1,000 mg/m(2) div at day 1, 8 and capecitabine 1,657 mg/m(2)/day p.o. at day 1-14, followed by a week rest period. Then, the regimen was repeated every 3 weeks. No treatment response was observed. There were two SD, three SD to PD, and two PD after a median of 3 cycles of treatment. The median time to disease progression was 9.1 months, and the one-year progression- free survival rate was 83%. Adverse effects were observed in 3 cases (37.5%), however, treatment was well tolerated. Despite the limited anti-tumor efficacy, it would be meaningful that the treatment brought disease stabilization to the majority of this group of patients.

Article in Japanese

Written by
Kobayashi M, Nakano K, Ikeda H, Nukui A, Suzuki K, Sugaya Y, Yuzawa M, Morita T.

Reference
Gan To Kagaku Ryoho. 2008 Feb;35(2):277-9.

PubMed Abstract
PMID:18281765

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!